Spark's Gene Therapy Luxturna Sails Through US FDA Panel

 
• By Sue Sutter
Blind pedestrian walking and detecting markings on tactile paving with textured ground surface indicators for blind and visually impaired.

More from US FDA Performance Tracker

More from Regulatory Trackers